Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Events IgAN

A New Dawn for IgA Nephropathy – 
Redefining What is Possible with Sparsentan Presented by Travere and ISN

March 11, 2025

Virtual

See Materials
Publications IgAN

Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice

View
Publications IgAN

Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis

View
Medical Information IgAN

Measures of Proteinuria in IgA Nephropathy

Learn more
Rkd-newss IgAN

ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy

Publications IgAN

The Humanistic Burden of Immunoglobulin A Nephropathy on Patients and Care-Partners in the United States

View
Publications FSGS

Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease

View
Medical Information IgAN

FILSPARI (sparsentan): Patient-reported Outcomes in the Phase 3 PROTECT Study

Learn more
Publications IgAN

Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial

View
Publications IgAN

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy

View
Publications IgAN

Sparsentan Ameliorates Glomerular Hypercellularity and Inflammatory-gene Networks Induced by IgA1-IgA Immune Complexes in a Mouse Model of IgA Nephropathy

View
Publications IgAN

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

View
Publications IgAN

Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

View